1,3-Thiazolidine-4-Ones: Copper Nickel Oxide Bimetallic Nanoparticle Catalysed Synthesis, Anticancer Potential and Molecular Modeling Studies

IF 0.6 4区化学 Q4 CHEMISTRY, APPLIED

Russian Journal of Applied Chemistry Pub Date : 2025-05-13 DOI:10.1134/S1070427223601924

Ramesh L. Sawant, Manisha R. Sawant, Jyoti B. Wadekar, Ganesh D. Barkade, Havagiray R. Chitme

{"title":"1,3-Thiazolidine-4-Ones: Copper Nickel Oxide Bimetallic Nanoparticle Catalysed Synthesis, Anticancer Potential and Molecular Modeling Studies","authors":"Ramesh L. Sawant, Manisha R. Sawant, Jyoti B. Wadekar, Ganesh D. Barkade, Havagiray R. Chitme","doi":"10.1134/S1070427223601924","DOIUrl":null,"url":null,"abstract":"Cancer is a leading cause of death worldwide. Inhibiting mitosis is the most effective clinical technique for cancer treatment. In this investigation, copper-nickel oxide nanoparticles synthesized by electrochemical synthesis and analysed by UV-visible spectrophotometer (UV 1800 Shimadzu), a Fourier transform infrared spectrophotometer (FTIR Affinity 1 Shimadzu), a thermogravimetric analyser (TGA 50 Thermoanalyzer Shimadzu), a high-end X-ray diffractometer, scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS), and transmission electron microscopy elected area electron diffraction (TEM-SAED) techniques. The calcinated copper nickel oxide nanoparticles were used successfully as a catalyst to synthesis of 2-(2-substituted-4-oxothiazolidin-3-yl)-1,9-dihydro-purin-6-ones. The title compounds were characterized by melting point, IR, 1H NMR, 13C NMR and LC-HRMS/MS spectroscopy. Using Sulforhodamine B (SRB) test, all newly synthesized compounds were evaluated in vitro for anti-cancer, anti-inflammatory, antioxidant, and angiogenesis activities. The compounds GB-6, GB-8, GB-10 exhibited significant in vitro anti-inflammatory activityin the range of IC50:179.65-194.59 μg/ml as compared with aceclofenac (IC50: 191.19 μg/mL) and the antioxidant activity by DPPH radical scavenging assay the compounds GB-6 (IC50: 11.96 μg/mL), GB-8 (IC50:10.67 μg/mL) and GB-10 (IC50: 9.08 μg/mL) exhibited excellent radical scavenging activities compared to ascorbic acid (IC50:13.04 μg/mL) and by the KMnO4 radical scavenging assay the compounds GB-2 (IC50: 15.33 μg/mL), GB-4 (IC50: 23.60 μg/mL), GB-8 (IC50: 24.93 μg/mL), GB-10 (IC50: 24.96 μg/mL) exhibited good radical scavenging activities compared to ascorbic acid (IC50: 26.55 μg/mL). Further development of anticancer drugs may be enabled by the discovery of related compounds to the anticancer agent, such as compound (GB-6), compound (GB-8), and compound (GB-10) as polo-like kinase 1 inhibitors.","PeriodicalId":757,"journal":{"name":"Russian Journal of Applied Chemistry","volume":"97 12","pages":"899 - 918"},"PeriodicalIF":0.6000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Applied Chemistry","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1134/S1070427223601924","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}

引用次数: 0

Abstract

Cancer is a leading cause of death worldwide. Inhibiting mitosis is the most effective clinical technique for cancer treatment. In this investigation, copper-nickel oxide nanoparticles synthesized by electrochemical synthesis and analysed by UV-visible spectrophotometer (UV 1800 Shimadzu), a Fourier transform infrared spectrophotometer (FTIR Affinity 1 Shimadzu), a thermogravimetric analyser (TGA 50 Thermoanalyzer Shimadzu), a high-end X-ray diffractometer, scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS), and transmission electron microscopy elected area electron diffraction (TEM-SAED) techniques. The calcinated copper nickel oxide nanoparticles were used successfully as a catalyst to synthesis of 2-(2-substituted-4-oxothiazolidin-3-yl)-1,9-dihydro-purin-6-ones. The title compounds were characterized by melting point, IR, ¹H NMR, ¹³C NMR and LC-HRMS/MS spectroscopy. Using Sulforhodamine B (SRB) test, all newly synthesized compounds were evaluated in vitro for anti-cancer, anti-inflammatory, antioxidant, and angiogenesis activities. The compounds GB-6, GB-8, GB-10 exhibited significant in vitro anti-inflammatory activityin the range of IC₅₀:179.65-194.59 μg/ml as compared with aceclofenac (IC₅₀: 191.19 μg/mL) and the antioxidant activity by DPPH radical scavenging assay the compounds GB-6 (IC₅₀: 11.96 μg/mL), GB-8 (IC₅₀:10.67 μg/mL) and GB-10 (IC₅₀: 9.08 μg/mL) exhibited excellent radical scavenging activities compared to ascorbic acid (IC₅₀:13.04 μg/mL) and by the KMnO₄ radical scavenging assay the compounds GB-2 (IC₅₀: 15.33 μg/mL), GB-4 (IC₅₀: 23.60 μg/mL), GB-8 (IC₅₀: 24.93 μg/mL), GB-10 (IC₅₀: 24.96 μg/mL) exhibited good radical scavenging activities compared to ascorbic acid (IC₅₀: 26.55 μg/mL). Further development of anticancer drugs may be enabled by the discovery of related compounds to the anticancer agent, such as compound (GB-6), compound (GB-8), and compound (GB-10) as polo-like kinase 1 inhibitors.

查看原文本刊更多论文

1,3-噻唑烷-4- ones：铜镍氧化物双金属纳米颗粒催化合成、抗癌潜力及分子模拟研究

癌症是世界范围内导致死亡的主要原因。抑制有丝分裂是治疗肿瘤最有效的临床技术。本研究采用电化学合成方法合成了氧化铜镍纳米颗粒，并通过紫外可见分光光度计（UV 1800 Shimadzu）、傅里叶变换红外分光光度计（FTIR Affinity 1 Shimadzu）、热重分析仪（TGA 50 Thermoanalyzer Shimadzu）、高端x射线衍射仪、扫描电子显微镜-能量色散能谱（SEM-EDS）和透射电子显微镜选择区电子衍射（TEM-SAED）技术进行了分析。以煅烧的铜镍氧化物纳米颗粒为催化剂，成功合成了2-（2-取代-4-氧噻唑烷-3-基）-1,9-二氢嘌呤-6-酮。采用熔点、IR、1H NMR、13C NMR和LC-HRMS/MS对化合物进行了表征。采用硫代丹胺B （Sulforhodamine B， SRB）试验，对新合成的化合物进行体外抗癌、抗炎、抗氧化和血管生成活性评价。化合物GB-6、GB-8、GB-10在IC50:179.65 ~ 194.59 μg/ml范围内与乙酰氯芬酸（IC50: 191.19 μg/ml）相比具有显著的体外抗炎活性；DPPH自由基清除实验表明，化合物GB-6 （IC50: 11.96 μg/ml）、GB-8 （IC50:10.67 μg/ml）和GB-10 （IC50: 9.08 μg/ml）的抗氧化活性与抗坏血酸（IC50:13.04 μg/ml）和KMnO4自由基清除实验表明，化合物GB-2 (IC50：与抗坏血酸（IC50: 26.55 μg/mL）相比，GB-4 （IC50: 23.60 μg/mL）、GB-8 （IC50: 24.93 μg/mL）、GB-10 （IC50: 24.96 μg/mL）具有较好的自由基清除能力。发现与抗癌剂相关的化合物，如化合物（GB-6）、化合物（GB-8）和化合物（GB-10）作为polo样激酶1抑制剂，可能会促进抗癌药物的进一步开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Russian Journal of Applied Chemistry 化学-应用化学

CiteScore

1.60

自引率

11.10%

发文量

审稿时长

2-4 weeks

期刊介绍： Russian Journal of Applied Chemistry (Zhurnal prikladnoi khimii) was founded in 1928. It covers all application problems of modern chemistry, including the structure of inorganic and organic compounds, kinetics and mechanisms of chemical reactions, problems of chemical processes and apparatus, borderline problems of chemistry, and applied research.